{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:11:15Z","timestamp":1772453475041,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite advances in stent design and PCI optimization, stent failure remains clinically relevant in patients with coronary artery disease. This process is primarily driven by vascular injury and maladaptive healing, leading to neointimal hyperplasia, neoatherosclerosis, and recurrent ischemic events. A subset of patients remains vulnerable despite angiographically successful PCI, reflecting residual risk not fully captured by procedural assessment alone. Novel strategies to reduce this residual risk are therefore warranted. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors, beyond potent LDL-C reduction, have demonstrated plaque-stabilizing effects. Preclinical data suggest that PCSK9 promotes proinflammatory cytokine release, vascular smooth muscle cell proliferation, and impaired endothelial repair\u2014mechanisms implicated in adverse vascular responses after PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To determine whether proactive, short-term evolocumab improves outcomes in patients with coronary artery disease at high residual risk after PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The HANYANG-PICK trial is a prospective, randomized, open-label, multicenter study enrolling patients with post-PCI\n                      <jats:sub>max<\/jats:sub>\n                      LCBI\n                      <jats:sub>4mm<\/jats:sub>\n                      \u2265200 on NIRS-IVUS. Participants will be randomized 1:1 to standard care or standard care plus evolocumab 140\u2005mg subcutaneously within 24\u2005h of PCI and at 2 weeks. The primary endpoint is the composite of all-cause death, myocardial infarction, stroke, or any clinically driven revascularization at 12 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol has been approved by the Institutional Review Board of all participating centers. Written informed consent will be obtained from all participants. Results will be disseminated in peer-reviewed journals and at scientific conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The HANYANG-PICK trial is an exploratory, hypothesis-generating randomized study designed to test whether proactive, short-term PCSK9 inhibition initiated during the early post-PCI period can reduce adverse outcomes in patients with high residual risk identified by post-PCI intravascular imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT07084259<\/jats:ext-link>\n                      , Identifier NCT07084259.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1761093","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:41:12Z","timestamp":1772451672000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Proactive, short-term PCSK9 inhibition after PCI in patients with coronary artery disease at high residual risk: rationale and design of the randomized HANYANG-PICK trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Woohyeun","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soojung","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Hanyang University Seoul Hospital","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Hun","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Guri Hospital","place":["Guri, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyungdon","family":"Kook","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hyo","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jacc.2022.05.017","article-title":"Coronary in-stent restenosis: jACC state-of-the-art review","volume":"80","author":"Giustino","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.jacc.2011.10.909","article-title":"In-Stent neoatherosclerosis","volume":"59","author":"Park","year":"2012","journal-title":"JACC"},{"key":"B3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/01.RES.84.4.378","article-title":"Balloon-Artery interactions during stent placement","volume":"84","author":"Rogers","year":"1999","journal-title":"Circ Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e006910","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.jacc.2023.08.019","article-title":"Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy","volume":"82","author":"Biccir\u00e8 Flavio","year":"2023","journal-title":"JACC"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC: Cardiovascular Imaging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1038\/s41467-024-46336-2","article-title":"PCSK9 Stimulates syk, PKC\u03b4, and NF-\u03baB, leading to atherosclerosis progression independently of LDL receptor","volume":"15","author":"Shin","year":"2024","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/ph15070802","article-title":"Impact of PCSK9 inhibition on proinflammatory cytokines and matrix metalloproteinases release in patients with mixed hyperlipidemia and vulnerable atherosclerotic plaque","author":"Basiak","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10753-022-01715-z","article-title":"PCSK9 Promotes endothelial dysfunction during sepsis via the TLR4\/MyD88\/NF-\u03baB and NLRP3 pathways","volume":"46","author":"Huang","year":"2023","journal-title":"Inflammation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.3390\/ijms22084114","article-title":"PCSK9 Induces rat smooth muscle cell proliferation and counteracts the pleiotropic effects of simvastatin","volume":"22","author":"Lupo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"151081","DOI":"10.1016\/j.bbrc.2024.151081","article-title":"PCSK9 Promotes vascular neointimal hyperplasia through non-lipid regulation of vascular smooth muscle cell proliferation, migration, and autophagy","volume":"742","author":"Zhang","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.7150\/thno.83914","article-title":"PCSK9 Attenuates efferocytosis in endothelial cells and promotes vascular aging","volume":"13","author":"Liu","year":"2023","journal-title":"Theranostics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11079","DOI":"10.1038\/s41598-019-47242-0","article-title":"Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice","volume":"9","author":"Schuster","year":"2019","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 And inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.5551\/jat.55400","article-title":"An update on the role of PCSK9 in atherosclerosis","volume":"27","author":"Yurtseven","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"B19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","article-title":"Inhibiting PCSK9 - biology beyond LDL control","volume":"15","author":"Stoekenbroek","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","article-title":"Inflammation in acute myocardial infarction: the good, the bad and the ugly","volume":"45","author":"Matter","year":"2023","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/cells10061391","article-title":"Inflammation during percutaneous coronary intervention-prognostic value, mechanisms and therapeutic targets","volume":"10","author":"Tucker","year":"2021","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40204-018-0097-y","article-title":"Cardiovascular stents: overview, evolution, and next generation","volume":"7","author":"Borhani","year":"2018","journal-title":"Prog Biomater"},{"key":"B23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0735-1097(99)00486-6","article-title":"Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen","volume":"35","author":"Grewe","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1161\/ATVBAHA.120.315617","article-title":"Target lesion lipid content detected by near-infrared spectroscopy after stenting and the risk of subsequent target lesion failure","volume":"41","author":"Madder","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e017740","DOI":"10.1161\/CIRCIMAGING.124.017740","article-title":"Impact of post-PCI lipid core burden Index on angiographic and clinical outcomes: insights from NIRS-IVUS","volume":"18","author":"Kim","year":"2025","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1761093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:41:13Z","timestamp":1772451673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1761093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2026.1761093"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1761093","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1761093"}}